A Case of Dasatinib-induced Pleural Effusion Accompanied by Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, Successfully Treated with Saikanto
10.3937/kampomed.62.664
- VernacularTitle:ダサチニブによる胸水に対し柴陥湯が奏効したフィラデルフィア染色体陽性急性リンパ性白血病の1例
- Author:
Tomoaki FUKUDA
;
Tokutaro TSUDA
;
Tomoyuki HAYASAKI
;
Tetsuro OIKAWA
;
Toshihiko HANAWA
- Publication Type:Journal Article
- Keywords:
saikanto;
pleural effusion;
dasatinib;
acute lymphoblastic leukemia
- From:Kampo Medicine
2011;62(5):664-668
- CountryJapan
- Language:Japanese
-
Abstract:
We report a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in whom saikanto was effective against pleural effusion induced by dasatinib, which is a second-generation tyrosine kinase inhibitor. The patient was a 43-year-old female. After she was diagnosed with Ph+ALL, she received imatinib and other chemotherapy. One year later, she started to receive dasatinib because of imatinib intolerance (vomiting and diarrhea). After about seven months of taking dasatinib, she experienced chest/back pain and a cough; at that time her chest x-ray showed right-sided pleural effusion. She consulted our clinic three months later, for treatment of the hydrothorax that frequently recurred. We prescribed saikanto because she presented with epigastric tenderness diagnosed as shokekkyo, and the pleural effusion and clinical symptoms improved remarkably. Because of the good clinical course in this case, we consider that the decrease of pleural effusion was caused mainly by the immunoregulatory and anti-inflammatory activities of saikanto in addition to its activities to alleviate fluid retention.
